Procaps Group SA
NASDAQ:PROC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
IOI Corporation Bhd
KLSE:IOICORP
|
MY |
|
Boyd Gaming Corp
NYSE:BYD
|
US |
|
Indah Kiat Pulp & Paper Tbk PT
OTC:PIKQF
|
ID |
|
mBank SA
LSE:0DU3
|
PL |
|
Doma Holdings Inc
NYSE:DOMA
|
US |
|
I
|
Integrated Design & Engineering Holdings Co Ltd
TSE:9161
|
JP |
|
S
|
Solarvest Holdings Bhd
KLSE:SLVEST
|
MY |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (12.9), the stock would be worth $1.51 (37% upside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 9.4 | $1.1 |
0%
|
| 3-Year Average | 12.9 | $1.51 |
+37%
|
| 5-Year Average | 12.9 | $1.51 |
+37%
|
| Industry Average | 9.4 | $1.1 |
0%
|
| Country Average | 13.3 | $1.55 |
+41%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
$319m
|
/ |
Oct 2023
$33.8m
|
= |
|
|
$319m
|
/ |
Dec 2023
$82.1m
|
= |
|
|
$319m
|
/ |
Dec 2024
$77.3m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| LU |
|
Procaps Group SA
NASDAQ:PROC
|
124.1m USD | 9.4 | 2.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
875.9B USD | 30.6 | 42.4 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
563.9B USD | 22 | 26.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
234.5B GBP | 23.6 | 30.4 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 12.9 | 19.4 | |
| CH |
|
Novartis AG
SIX:NOVN
|
225.3B CHF | 16.2 | 20.3 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
294.7B USD | 12.2 | 16.1 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 9.7 | 11.3 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
156.7B USD | 10.3 | 20.2 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
121.1B USD | 8.9 | 17.2 |
Market Distribution
| Min | 0 |
| 30th Percentile | 9.8 |
| Median | 13.3 |
| 70th Percentile | 22.5 |
| Max | 1 142.5 |
Other Multiples
Procaps Group SA
Glance View
Procaps Group SA develops pharmaceutical and nutraceutical solutions, medicines, and hospital supplies. The firm develops, manufactures and sells prescription drugs and products that are differentiated by their combinations and pharmaceutical forms, as well as nutritional supplements which include omega 3 fish oils and high-potency clinical compounds. The company operates its business through 5 units which are Diabetrics, Farma Procaps, Softi Gel, Vital Care, and Clinical Specialties. Diabetrics provides diabetes solutions. Farma procaps formulates, manufactures and markets branded prescription drugs in Latin America. Softi Gel provides contract drug development and manufacturing services to third party pharmaceutical companies. Vital Care develops, manufactures and markets consumer healthcare products. Clinical Specialties develops, manufactures and markets complex drugs.
